| Baseline | Day 1 | 3 months (± 14 days) | 6 months (± 14 days) | 9 months (± 14 days) | 12 months (± 14 days) | 18 months (± 14 days) | 24 months (± 14 days) |
---|---|---|---|---|---|---|---|---|
Assessment | ||||||||
 Informed consent | √ |  |  |  |  |  |  |  |
 CT of pelvis/abdomena | √ |  |  | √ |  | √ | √ | √ |
 CT chest (or chest X-ray) | √ |  |  | √ |  | √ | √ | √ |
 MRI of pelvis | √ |  |  | √ |  | √ | √ | √ |
 Pelvic ultrasonographyb | √ |  | √ | √ | √ | √ | √ | √ |
 CA125 | √ |  | √ | √ | √ | √ | √ | √ |
 FBG (fasting blood-glucose) | √ |  | √ | √ | √ | √ | √ | √ |
 Serum or urine pregnancy test | √ | √(urine) |  |  |  |  |  |  |
 Fasting blood sugar | √ |  | √ | √ | √ | √ | √ | √ |
 HbA1c | √ |  | √ | √ | √ | √ | √ | √ |
 HE4 (human epididymal protein4) | √ |  | √ | √ | √ | √ | √ | √ |
 Blood collection for biomarkers and genetic testing | √ |  |  |  |  |  |  |  |
 ERα, PRα and PRβ (estrogen receptor, progesterone receptor) | ||||||||
 Medical history | √ |  |  |  |  |  |  |  |
 Concomitant medications | √ |  | √ | √ | √ | √ | √ | √ |
 ECOG | √ |  | √ | √ | √ | √ | √ | √ |
 Height | √ |  |  |  |  |  |  |  |
 Weight | √ |  | √ | √ | √ | √ | √ | √ |
 BMI | √ |  | √ | √ | √ | √ | √ | √ |
 Surgical, medical, gynecologic, and family history | √ |  |  |  |  |  |  |  |
 Self-efficacy and social support questionnaire | √ |  | √ | √ | √ | √ | √ | √ |
 Adverse events |  |  | √ | √ | √ | √ | √ | √ |
 Hysteroscopy, D&C |  |  | √ | √ | √ | √ | √ | √ |
 Intervention adherence |  |  | √ | √ | √ | √ | √ | √ |